Macrocyclic compounds as HCV entry inhibitors

US9624245B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Tao Wang · Farmington, US
• Zhongxing Zhang · Wallingford, US
• Zhiwei Yin · Glastonbury, US
• Li-Qiang Sun · Foster City, US
• Eric Mull · Guilford, US
• Qian Zhao · Louisville, US
• Paul Michael Scola · Glastonbury, US

Key dates

• Filing date: Feb 4, 2014
• Grant date: Apr 18, 2017
• Expiry date: Feb 4, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.